PURPOSE: Mechanically ventilated patients are at risk for developing ventilator-associated pneumonia which increases mortality in the intensive care unit. Bacterial infection may be introduced through respiratory equipments i.e. suction catheters that could become a fomite for infection. Proper aseptic techniques should be used to prevent bacterial colonization. The study aims to determine the presence and degree of bacterial growth on suction catheter tips used in intubated patients after being used for one and eight hour/s and to compare the in-vitro effect of 0.1% hexetidine, 1% and 0.5% acetic acid and sterile NSS in inhibiting bacterial growth.
METHODS: This is a prospective double blinded experimental study determining the presence and degree of bacterial growth on suction tips used after 1-hour and 8-hours. Afterwhich, the in-vitro effect, defined by the zone of inhibition, produced by 0.1% hexetidine, 1% acetic acid, 0.5% acetic acid, and sterile NSS on the bacterial growth were measured. Suction catheter tips were collected from patients aged 18 years old and above, orally intubated or on tracheostomy tube who required ventilatory support for at least 24 hours, admitted at the intensive care units of the University of Santo Tomas Hospital from August 2009 - October 2009.
RESULTS: Ninety-one percent of suction tips used for eight hours were positive for bacterial growth as compared to 54.5% of suction tips used for one-hour. In the 8-hour group, none of the solutions was comparable to the inhibitory effect of hexetidine. At one hour, 1% acetic acid was comparable with hexetidine in its capacity to inhibit growth of bacteria.
CONCLUSION: Hexetidine is effective in inhibiting bacterial growth in suction catheters even after 8-hour use. One percent acetic acid is comparable to hexetidine in its efficacy in inhibiting bacterial growth on suction tips at one hour of use.
CLINICAL IMPLICATIONS: One percent acetic acid may therefore be used to inhibit bacterial growth on suction tips at one hour of use, it being comparable to 0.1% hexetidine.
DISCLOSURE: Mary Anne Chong, No Financial Disclosure Information; No Product/Research Disclosure Information